Thesis

189 Denosumab reduces lesional Fluoride skeletal burden on Na[18F]F PET-CT Table 2. Patient characteristics of the non-denosumab group Patient nr Treatment, reason Treatment dose Treatment Active or stopped Interval Scan 1, scan 2 (weeks) Interval Scan to BTM Scan 1 (weeks) Baseline SBS MFD/ PFD/ MAS Location FD 9 Pain progression APD (pamidronate) 1800mg for 1 year stopped 113 1.0 1.76 MFD Femur 10 Pain progression Zoledronate (15 mg) active 106 3.4 2.23 MFD Left tibia 11 Pain progression APD (pamidronate) for 1 year active 48 7.6 0.33 MFD Rib 12 Pain and BTMs progression Olpadronate orally and i.v. more than 4 years (formally APD, equivalent to osteoporosis dosage) stopped 89 12.4 17.87 PFD Sternum, iliac bone, femur and tibia 13 Pain and BTMs progression Olpadronate (50 mg) active 87 5.4 15.75 PFD Femur and tibia 14 Pain and BTMs progression Olpadronate (56 mg) active 100 12.6 16.42 PFD Ribs, femur and tibia 15 Pain and BTMs progression Olpadronate orally and i.v. active 117 11.4 15.75 PFD Humerus, pelvis, femur 8

RkJQdWJsaXNoZXIy MjY0ODMw